When Caroline Savage arrived at the Norfolk and Norwich University Hospital on the afternoon of 18 October 2024, the clinicians who examined her had a narrow window and an incomplete picture. She was 73, in acute abdominal pain, and had been taking Mounjaro for four months on a private prescription to manage her weight and lipoedema. They ruled out pancreatitis. They ruled out an aortic aneurysm. They administered morphine, reassessed her pain against a baseline it had already dulled, and sent her home with advice. She collapsed and died before midnight. The inquest now hearing evidence into her death has heard that diverticular perforation, the eventual cause, is notoriously difficult to predict. That may well be true. It is also beside the point.

The more useful question is not whether any individual clinician erred on a single afternoon, but what the system around them knew, and what it was designed to know. Savage's Mounjaro had been prescribed privately, through a doctor operating outside NHS oversight, with a dosage increase recently discussed and no shared record connecting that decision to the hospital she later walked into. This is not a fringe scenario. Well over two million people in Britain are now paying out of pocket for GLP-1 drugs like Mounjaro, roughly seven times the number receiving them through NHS pathways, and the gap between those two populations is not shrinking so much as becoming permanent. The NHS rollout remains slow and tightly rationed by BMI thresholds and comorbidity counts, while private clinics, pharmacies and online prescribers absorb the demand the health service cannot yet meet. Wes Streeting, the previous health secretary, spoke openly about the rise of what he called rogue prescribers exploiting that gap. The more mundane problem, illustrated starkly in Norwich, is what happens when entirely properly regulated private prescribing meets an NHS emergency department that has no systematic means of factoring it in.

A&E clinicians are trained to triage against the information in front of them, and the information in front of them was thin. Mounjaro's known side effects, abdominal pain and bloating among them, offered a plausible and comparatively benign explanation for Savage's symptoms. The family's barrister has argued that pain assessments were repeatedly made shortly after morphine had been given, without full appreciation of what that timing might obscure, and that record keeping fell short of what it should have been. The trust's own solicitor has accepted as much on documentation while defending the substance of the clinical judgment made. Both things can be true. What the case exposes is structural rather than personal: an emergency medicine workforce increasingly likely to encounter patients on powerful drugs prescribed entirely outside the NHS, working from records that were never built to capture that history, under the same time and staffing pressures that define urgent care across the country.

This has implications well beyond one Norfolk trust. As GLP-1 prescribing scales further under the 2026-27 GP contract and NHS eligibility slowly widens, the private market it is meant to shrink shows little sign of doing so, and the information gap between the two systems will keep producing cases like this one. NHS leaders and the MHRA have spent the past two years focused on regulating who can prescribe these drugs and under what criteria. Rather less attention has gone to what an NHS clinician is meant to do when a patient in front of them is already taking one, prescribed by someone who has no obligation to tell the hospital anything. Yvonne Blake, the coroner, has adjourned before delivering a narrative conclusion, and nothing here should presume what she will find. But the shape of the problem does not depend on her verdict. It sits in the space between two prescribing systems that were never designed to talk to each other, and patients are the ones falling through it.